Improved Blood Glucose Levels Research Articles

Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.

This report explores the potential role of glucagon-like peptide 1 (GLP-1) receptor agonists in minimizing the metabolic side effects of psychotropic medications in patients with underlying type 2 diabetes (T2D) in inpatient psychiatric settings. The introduction of novel antidiabetic medications such as GLP-1 receptor agonists has broadened the options for managing metabolic disorders, particularly T2D. These medications not only offer effective glycemic control but also provide cardiovascular and renal benefits and help with weight management. Given the tendency of psychotropic medications to cause weight gain and metabolic complications, this report presents 2 cases where weekly doses of semaglutide improved blood glucose levels and prevented weight gain in patients receiving chronic psychotropic medications. Integrating GLP-1 receptor agonists into inpatient psychiatric care can help mitigate the metabolic adverse effects of psychotropic medications. However, considerations such as cost, accessibility, and institutional formulary restrictions are essential to ensure comprehensive patient care.

Types of Intermittent Fasting and Their Effects on Obesity and Type II Diabetes Mellitus

Obesity and type II diabetes mellitus affect millions of people both in Malaysia and worldwide due to sedentary lifestyles and unhealthy diets. Intermittent fasting reduces calorie intake by interweaving eating periods with prolonged fasting periods on a recurring basis. Therefore, it could be a potential solution to induce weight loss, leading to improved blood glucose level as observed in type II diabetes mellitus individuals. However, its feasibility remains unclear. This review aimed to compare the beneficial effects and adverse reactions from different types of intermittent fasting in obese and type II diabetes mellitus studies. The review was carried out by combing through several online databases. Keywords such as “Intermittent fasting”, “Obesity”, “Type II Diabetes Mellitus” were used and relevant articles were selected. The findings of this review showed that intermittent fasting is feasible and effective in reducing body weight and improving blood glucose. The beneficial effects of intermittent fasting appear to outweigh the adverse reactions. Having said that, intermittent fasting is unsuitable for individuals with packed schedules and certain health conditions such as pregnancy. This review will hopefully shed light on intermittent fasting as a potential intervention to combat obesity and type II diabetes mellitus. Further exploration of intermittent fasting could reduce both the morbidity and mortality rates from non-communicable diseases globally.

HOW CASSIA ALATA L AFFECTS BLOOD GLUCOSE LEVELS IN DIABETES MELLITUS PATIENTS?

Candle bush (Cassia alata L.) are plants that are rich in antioxidants. There have been many studies that discuss the efficacy of Candle bush (Cassia alata L.) in skin diseases, but there is still less research that discusses the potential of Candle bush leaves as antidiabetics. Therefore, researchers want to test the effectiveness of Candle bush leaves (Cassia alata L.) in improving blood glucose levels (antidiabetic) using experimental animals (Rattus norvegicus strain wistar) induced with Streptozotosin (STZ). Candle bush leaf extract (Cassia alata L.) was made with maceration method using ethanol 70% solution. Experimental animals were divided into 6 groups. Group 1,2, and 3 are the control group, Group 4,5, and 6 are the groups that are given the extract with different doses each. This study proves that extract of Candle bush leaf (Cassia alata L.) can improve blood glucose levels of the experimental animals (Rattus norvegicus strain wistar).

Clinical Decision Support Systems to Identify Drug-Related Problems in Diabetes Mellitus Patients: A Systematic Review

Clinical Decision Support Systems (CDSSs) has been developed for utilization to provide rational therapy to Diabetes Mellitus (DM) patients including preventing Drug-related Problems (DRPs) such as the effect of drug treatment being not optimal, untreated indications and symptoms, unnecessary therapy, and adverse drug reactions. This study aims to summarize the available evidence on the intervention of CDSSs, key outputs, and impact of the user in DM patients. This study was a systematic review using PubMed, Scopus database, and by manually searching the bibliographies of articles that have been found. We included studies reporting on evaluated CDSSs that had been implemented in medication prescription, reducing medication errors, adverse drug events, drug-allergy checking, drug dosing support, and so on. A total of 8 studies were selected among 855 studies. CDSSs are used in hospitals and primary care settings to identify potential drug interactions, correct therapy regimens, monitor therapy, blood glucose documentation, ensure patients receive medication according to the guideline, provide nutritional advice, and schedule physical activity. The usage of CDSSs improves blood glucose levels, detects possible drug interactions, reduces face-to-face consultations, improves documentation, assists in identifying dose, and promotes prescribing in line with the guideline. The use of CDSSs can help to reduce the risk of errors in management therapy.

An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models.

Appropriate management of blood glucose levels and the prevention of complications are important in the treatment of diabetes. We have previously reported on a compound named HPH-15 that is not only antifibrotic but also AMP-activated protein kinase (AMPK)-activating. In this study, we evaluated whether HPH-15 is useful as a therapeutic medication for diabetes. We examined the effects of HPH-15 on AMPK activation, glucose uptake, fat accumulation and lactic acid production in L6-GLUT4, HepG2 and 3T3-L1 cells, as a model of muscle, liver and fat tissue, respectively. Additionally, we investigated the glucose-lowering, fat-accumulation-suppressing, antifibrotic and AMPK-activating effect of HPH-15 in mice fed a high-fat diet (HFD). HPH-15 at a concentration of 10 µmol/l increased AMPK activation, glucose uptake and membrane translocation of GLUT4 in each cell model to the same extent as metformin at 2 mmol/l. The production of lactic acid (which causes lactic acidosis) in HPH-15-treated cells was equal to or less than that observed in metformin-treated cells. In HFD-fed mice, HPH-15 lowered blood glucose from 11.1±0.3 mmol/l to 8.2±0.4 mmol/l (10 mg/kg) and 7.9±0.4 mmol/l (100 mg/kg) and improved insulin resistance. The HPH-15 (10 mg/kg) group showed the same level of AMPK activation as the metformin (300 mg/kg) group in all organs. The HPH-15-treated HFD-fed mice also showed suppression of fat accumulation and fibrosis in the liver and fat tissue; these effects were more significant than those obtained with metformin. Mice treated with high doses of HPH-15 also exhibited a 44% reduction in subcutaneous fat. HPH-15 activated AMPK at lower concentrations than metformin in vitro and in vivo and improved blood glucose levels and insulin resistance in vivo. In addition, HPH-15 was more effective than metformin at ameliorating fatty liver and adipocyte hypertrophy in HFD-fed mice. HPH-15 could be effective in preventing fatty liver, a common complication in diabetic individuals. Additionally, in contrast to metformin, high doses of HPH-15 reduced subcutaneous fat in HFD-fed mice. Presumably, HPH-15 has a stronger inhibitory effect on fat accumulation and fibrosis than metformin, accounting for the reduction of subcutaneous fat. Therefore, HPH-15 is potentially a glucose-lowering medication that can lower blood glucose, inhibit fat accumulation and ameliorate liver fibrosis.

Association of Physical Activity and Dietary Diversity with Cognitive Function in the Elderly with Type 2 Diabetes Mellitus: Findings from a Cross-Sectional Study

Aims Mild cognitive impairment (MCI) is a common complication of type 2 diabetes mellitus (T2DM). Changes in lifestyle and dietary patterns play a crucial role in preventing both diabetes and cognitive impairment. Methods A cross-sectional study was conducted on 899 aging participants. The Dietary Diversity Score (DDS) was used to evaluate dietary diversity. The physical activity (PA) levels were divided based on metabolic equivalents and weekly activity time. Individual PA levels were further re-scored and combined with DDS scores to obtain each participant’s total score. Results Regardless of T2DM status, individuals with MCI had lower DDS and plant-derived DDS compared to non-MCI individuals. Non-MCI subjects had higher total PA and DDS scores than MCI subjects. There were differences in the correlation between DDS or PA scores and blood glucose and MoCA scores among different groups. The subjects with high DDS levels showed a significantly decreased risk of MCI and T2DM + MCI. Those with a total PA and DDS score in Q4 showed a significantly decreased risk of MCI and T2DM + MCI compared to Q1. Conclusions A diversified diet improved blood glucose levels and cognitive function. Elderly individuals with diverse diets and adequate PA had a reduced risk of developing T2DM and MCI.

Antidiabetic potential of fenugreek (Trigonella foenum-graecum): A magic herb for diabetes mellitus.

Fenugreek (Trigonella foenum-graecum) is a widely grown dietary herb in Asia, and its seeds are traditionally used for several diseases, including diabetes. The seeds and leaves possess a variety of compounds that play an important role in regulating their hypoglycemic effect. However, so far, no extensive systematic review exists on its antidiabetic effect, highlighting the molecular mechanisms and isolated compounds. The purpose of this review is to summarize the preclinical and clinical antidiabetic properties of fenugreek and its isolated compounds by focusing on underlying mechanisms. PubMed, Google Scholar, Science Direct, and Scopus databases were searched to retrieve articles until June, 2024. Preclinical studies demonstrated that the antidiabetic effect of fenugreek was mostly associated with enhanced glucose transporter type-4 (GLUT4) translocation and hexokinase activity, decreased glucose-6-phosphatase and fructose-1,6-bisphosphatase activities, inhibited α-amylase and maltase activities, protected β cells, and increased insulin release. Furthermore, few studies have reported its role as a glucagon-like peptide-1 (GLP-1) modulator, 5'-AMP-activated kinase (AMPK) activator, and dipeptidyl peptidase-IV (DPP-IV) inhibitor. Further clinical trials showed that fenugreek seeds improved blood glucose levels, insulin resistance, insulin sensitivity, and lipid profiles. This study highlights significant evidence of the antidiabetic effect of fenugreek and its isolated compounds; therefore, it could be a potential therapy for diabetes.

6'-Sialyllactose Alleviates Muscle Fatigue through Reduced Blood Lactate Level after Treadmill Exercise in Mice.

6'-Sialyllactose (6'-SL), found in human breast milk, exhibits anti-inflammatory, immune function-enhancing, brain development-promoting, and gut health-improving effects. However, its effects on muscle fatigue remain unknown. Here, we aimed to investigate the effects of 6'-SL on blood lactate level, muscle fiber type, and oxidative phosphorylation protein complexes (OXPHOS) in muscle after exercise using C57BL/6J male mice. C57BL/6J mice were randomly assigned to control or 100 mg/kg 6'-SL. After 12 weeks of 6'-SL administration, the mice were made to perform treadmill exercise; their blood lactate and glucose levels were measured at the basal level (rest) and 0, 5, and 10 min after treadmill exercise. Results showed that 6'-SL treatment in C57BL/6J mice significantly reduced blood lactate level and improved blood glucose level. Moreover, 6'-SL increased the expression of slow-myosin heavy chain (MHC) and OXPHOS in gastrocnemius muscle. In addition, 6'-SL treatment for 12 weeks did not affect food intake, serum biomarkers of tissue injury, and lipid profiles compared with those of the controls. These findings indicate that non-toxic 6'-SL suppressed muscle fatigue during exercise by promoting protein expression of muscle fibers, especially slow-twitch muscle fibers characterized by abundant OXPHOS complexes and decreased blood lactate level. This study suggests that 6'-SL holds promise as a nutritional supplement in exercise and clinical settings, subject to further validation.

Cordycepin Ameliorates High Fat Diet-Induced Obesity by Modulating Endogenous Metabolism and Gut Microbiota Dysbiosis.

Numerous metabolic illnesses have obesity as a risk factor. The composition of the gut microbiota and endogenous metabolism are important factors in the onset and progression of obesity. Recent research indicates that cordycepin (CRD), derived from fungi, exhibits anti-inflammatory and antioxidant properties, showing potential in combating obesity. However, further investigation is required to delineate its precise impacts on endogenous metabolism and gut microbiota. In this work, male C57BL/6J mice were used as models of obesity caused by a high-fat diet (HFD) and given CRD. Mice's colon, liver, and adipose tissues were stained with H&E. Serum metabolome analysis and 16S rRNA sequencing elucidated the effects of CRD on HFD-induced obese mice and identified potential mediators for its anti-obesity effects. CRD intervention alleviated HFD-induced intestinal inflammation, improved blood glucose levels, and reduced fat accumulation. Furthermore, CRD supplementation demonstrated the ability to modulate endogenous metabolic disorders by regulating the levels of key metabolites, including DL-2-aminooctanoic acid, inositol, and 6-deoxyfagomine. CRD influenced the abundance of important microbiota such as Parasutterella, Alloprevotella, Prevotellaceae_NK3B31_group, Alistipes, unclassified_Clostridia_vadinBB60_group, and unclassified_Muribaculaceae, ultimately leading to the modulation of endogenous metabolism and the amelioration of gut microbiota disorders. According to our research, CRD therapies show promise in regulating fat accumulation and stabilizing blood glucose levels. Furthermore, through the modulation of gut microbiota composition and key metabolites, CRD interventions have the dual capacity to prevent and ameliorate obesity.

Therapeutic effect of oral insulin-chitosan nanobeads pectin-dextrin shell on streptozotocin-diabetic male albino rats

The current study inspects the therapeutic effects of orally ingested insulin-loaded chitosan nanobeads (INS-CsNBs) with a pectin-dextrin (PD) coating on streptozotocin (STZ)-induced diabetes in Wistar rats. The study also assessed antioxidant effects in pancreatic tissue homogenate, insulin, C-peptide, and inflammatory markers interleukin-1 beta and interleukin-6 (IL-1β and IL-6) in serum. Additionally, histopathological and immunohistochemical examination of insulin granules, oxidative stress, nuclear factor kappa B (NF-κB P65), and sirtuin-1 (SIRT-1) protein detection, as well as gene expression of nuclear factor erythroid 2–related factor 2 (Nrf2), heme oxygenase-1 (HO-1), B-cell lymphoma 2 (Bcl2), and Bcl-2-associated X protein (Bax) in pancreatic tissue were investigated. After induction of diabetes with STZ, rats were allocated into 6 groups: the normal control (C), the diabetic control (D), and the diabetic groups treated with INS-CsNBs coated with PD shell (50 IU/kg) (NF), free oral insulin (10 IU/kg) (FO), CsNBs-PD shell (50 IU/kg) (NB), and subcutaneous insulin (10 IU/kg) (Sc). The rats were treated daily for four weeks. Treatment of diabetic rats with INS-CsNBs coated with PD shell resulted in a significant improvement in blood glucose levels, elevated antioxidant activities, decreased NF-κB P65, IL-1β, and IL-6 levels, upregulated Nrf-2 and HO-1, in addition to a marked improvement in the histological architecture and integrity compared to the diabetic group. The effects of oral INS-CsNBs administration were comparable to those of subcutaneous insulin. In conclusion, oral administration of INS-loaded Cs-NBs with a pectin-dextrin shell demonstrated an ameliorative effect on STZ-induced diabetes, avoiding the drawbacks of subcutaneous insulin.

Ketogenic Diet and Its Potential Role in Preventing Type 2 Diabetes Mellitus and Its Complications: A Narrative Review of Randomized Controlled Trials.

Diabetes mellitus is a global health crisis affecting millions. Nutrition plays a vital role in its management and prevention. While carbohydrate reduction is beneficial for glycemic control, various dietary approaches exist. The ketogenic diet, characterized by very low carbohydrate intake, has shown promise in weight management and blood sugar control. However, its potential for preventing type 2 diabetes mellitus (T2DM) remains largely unexplored. To evaluate the ketogenic diet's potential in preventing T2DM, this review searched the PubMed database for studies published between 2013 and 2023. Findings suggest that the diet can effectively aid weight loss and improve blood glucose levels. Some evidence indicates reduced reliance on diabetes medications. However, effects on cholesterol levels are inconsistent, and long-term adherence challenges exist. Additionally, potential micronutrient deficiencies and safety concerns require careful consideration. While the ketogenic diet offers potential benefits, further research is needed to establish its efficacy and safety as a long-term prevention strategy for T2DM. However, the results of the present study indicate the need for further research in this area, utilizing rigorous methodology.

Highly purified hypochlorous acid water facilitates glucose metabolism and memory formation in type 2 diabetic mice associated with altered-gut microbiota

Hypochlorous acid (HOCl) is an endogenous oxidant and chlorinating agent in mammals that is effective against a broad range of microorganisms. However, the effects of exogenous HOCl on biological processes have not been reported. In this study, the effects of highly purified slightly acidic hypochlorous acid water (HP-HAW) were investigated. After the safety of oral administration of HP-HAW was confirmed, the effects of HP-HAW on glucose homeostasis were assessed in mice. HP-HAW treatment significantly improved blood glucose levels in hyperglycemic condition. Based on the 16S rRNA sequencing, HP-HAW treatment significantly increased the diversity and changed the composition of gut microbiota by decreasing the abundance of genus Romboutsia in mice fed normal chow. In obese mice, HP-HAW administration tended to improve glucose tolerance. HP-HAW also attenuated memory impairments and changes N-methyl-d-aspartate (NMDA) receptor mRNA expression in obese mice. HP-HAW treatment suppressed Il-6 mRNA expression in the hippocampus in type 2 diabetic mice. Overall, these results support HP-HAW as a potential therapeutic agent to improve or prevent glucose tolerance and memory decline via gut microbiota alteration.

Effect of Omega-3 Fatty Acids Supplementation in Pediatric Patients with Type 1 Diabetes Mellitus

Abstract Background Omega-3 fatty acids (O3FAs) are polyunsaturated fatty acids derived from fish oil. Beneficial effects of O3FA supplementation in a wide range of disease condition have been well studied. However; the role of O3FA in management of type 1 diabetes mellitus (T1DM) remains unclear and controversial. Objectives Therefore, we performed a randomized-controlled trial to assess the effect of oral O3FAssupplementation on glycemic control and lipid profile in pediatric patients with T1DM. Methods This study included 70 children and adolescents with T1DM. Patients were randomly assigned into two groups; intervention group and received oral O3FAs capsules (1 gram daily). The other group did not receive any supplementation and served as a control group. Both groups were followed-up for 6 months with assessment of fasting blood glucose (FBG), HbA1c and fasting lipids. Results Supplementation with O3FAs was safe and well-tolerated. After 6 months, O3FAs adjuvant therapy for the intervention group resulted in a significant decrease of systolic blood pressure, insulin dose, FBG, HbA1c, triglycerides, total cholesterol and LDL-cholesterol compared with baseline levels and compared with the control group (p < 0.05). On the other hand, T1DM patients without O3FAs adjuvant therapy (control group) had higher blood glucose levels and HbA1c at study end compared with baseline levels (p < 0.001). Conclusions O3FAs as an adjuvant therapy to insulin improved blood glucose levels, glycemic control and dyslipidemia leading to reduction in insulin dose in pediatric patients with T1DM.

Efficacy and Safety of Resveratrol in Patients with Type 1 Diabetes Mellitus

Abstract Background Resveratrol is a food component found in grapes, peanuts, cranberries.. It has a wide range of effects including antimicrobial, anti-inflammatory and anti-apoptotic effects. Resveratrol could ameliorate diabetes in diabetic animals and it showed beneficial effects in adults with type 1 diabetes mellitus (T1DM). Objectives This randomized-controlled trial assessed the efficacy and safety of oral resveratrol supplementation on glycemic control and lipid profile in pediatric patients with T1DM. Methods This study included 60 children and adolescents with T1DM. Enrolled patients aged 12- 18 years with disease duration > 5 years. Patients were randomly assigned into two groups; intervention group who received oral resveratrol tablets 250 mg twice daily. The other group (did not receive any supplementation and served as a control group. Both groups were followed-up for 6 months with assessment of fasting blood glucose (FBG), HbA1c% and fasting lipid profile. Results After 6 months, resveratrol therapy resulted in a significant decrease of FBG, HbA1c, triglycerides and total cholesterol compared with baseline levels and compared with the control group (p < 0.001). No significant difference was found between Patients with T1DM without resveratrol adjuvant therapy at baseline and at 6 months as regards any of the studied variables except for triglycerides and total cholesterol which were significantly increased at study end. Conclusions Resveratrol as an adjuvant therapy to insulin improved blood glucose levels, glycemic control and dyslipidemia without adverse effects in pediatric patients with T1DM.

Exploring the Therapeutic Potential of Lepidagathis pungens Nees Extracts as Novel Therapy Options in Streptozotocin and Nicotinamide-Induced Diabetes in Albino Wistar Rats

Diabetes mellitus remains a global health concern, necessitating innovative therapeutic approaches. This study explores the antidiabetic potential of aqueous and methanol extracts from Lepidagathis pungens Nees in albino Wistar rats induced with diabetes. Diabetes induction involves the administration of streptozotocin (STZ) and nicotinamide (NIC), mimicking pathological conditions observed in human diabetes. The study employed aqueous and methanol extracts of L. pungens Nees alongside a standard drug, glibenclamide. Diabetes induction was achieved through intraperitoneal injection of STZ and NIC. Extracts and the standard drug were orally administered, and various parameters, including blood glucose levels, body weight changes, insulin and hemoglobin levels, as well as liver and lipid profiles, were monitored at specified intervals. Furthermore, liver and pancreas tissues were evaluated histopathologically. In comparison to the diabetic group, both aqueous and methanol extracts demonstrated significant antidiabetic activity (p <0.001), with effects comparable to or better than the standard drug. A remarkable improvement in insulin and hemoglobin levels was observed, along with significant improvements in blood glucose levels and body weight changes. Furthermore, the extracts demonstrated positive effects on liver and lipid profiles, exhibiting potential to mitigate diabetes-induced complications. Histopathological studies revealed protective effects on liver and pancreas tissues, supporting the extracts’ therapeutic efficacy. In STZ- and NIC-induced diabetic rats, L. pungens Nees extracts show promising antidiabetic activity. The extracts demonstrated significant improvements in various physiological parameters, suggesting their potential as alternative or adjunctive therapies in the management of diabetes. Further research and clinical investigations are warranted to elucidate the underlying mechanisms and translate these findings into practical therapeutic applications.

Insulinoma in a Boxer- A case report

A nine-year-old female Boxer was presented to the Small Animal Medicine outpatient unit of Teaching Veterinary Hospital, Madras Veterinary College with the complaint of weakness and occasional ataxia. The general clinical, physical and neurological examinations were found to be normal except for the history of weakness and ataxia. The complete blood count was normal. Serum biochemistry revealed hypoglycemia and the amended insulin to glucose ratio was 187.4. Abdominal ultrasonography and radiography examination were unrewarding. Contrast CT revealed presence of multiple nodular lesions over the pancreas suggestive of insulinoma. The hypoglycemic episodes were managed with dextrose solution followed by dietary management, prednisolone and octreotide. The animal responded to treatment with an improvement in blood glucose level.

Analysis of The Effect of Comprehensive Nursing Intervention on Improving Blood Sugar Levels and Treatment Compliance in Elderly Patients with Diabetes

Objective: To analyze the effect of comprehensive nursing intervention on improving blood glucose levels and treatment compliance in elderly patients with diabetes. Methods: One hundred and forty-eight elderly patients with diabetes were selected and randomly divided into a control group and an observation group, with 74 cases each. The control group received routine nursing intervention and the observation group received comprehensive nursing intervention. The blood sugar levels, treatment compliance, and nursing satisfaction of the two groups of patients before and after intervention were compared. Results: After the intervention, the fasting plasma glucose (FPG) (t = 7.729), 2 hours postprandial glucose (PPG) (t = 8.343), and HbA1c (t = 6.929) levels of patients in the observation group were significantly lower than those in the control group (P < 0.001). The observation group (71/95.95%) had a higher compliance rate than the control group (54/72.97%) (χ2 =14.877, P < 0.001). The comprehensive nursing satisfaction rate of the observation group (73/98.65%) was higher than that of the control group (56/75.68%) (χ2 =17.451, P < 0.001). Conclusion: In caring for elderly patients with diabetes, comprehensive nursing intervention effectively reduced patients’ blood sugar levels and improved treatment compliance and nursing satisfaction.

Dual targeting of inflammation and β-cell dysfunction for therapy of diabetes mellitus

Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by β-cell loss and inflammation. From a therapeutic standpoint, it would be necessary to halt the uncontrolled inflammatory response and to enable the regeneration of the damaged β-cells. In this work, to achieve the latter two drug-loaded nanocarrier systems have been developed and evaluated in-vivo in DM mouse model. For β-cell proliferation, small chitosan (CS) nanoparticles (NPs) (201 ± 30 nm) were loaded with 4b, a selective inhibitor of DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A). To reduce inflammation, large poly lactic-co-glycolic acid (PLGA) microparticles (MPs) (1172 ± 77 nm) were encapsulated with BI-605906, an inhibitor of IKKβ (inhibitor of kappa B kinase beta), acting as an inhibitor of an inhibitor. The EE% values were 90 ± 4.2 % and 87 ± 4.46 % for 4b–CS–NPs and BI-605906-PLGA-MPs, respectively. In-vivo biodistribution studies indicated the ability of both particles to accumulate in the pancreas. For CS-NPs, this was achieved as a function of the increased vascular permeability in DM, whereas for PLGA-MPs, this was achieved as function of macrophage uptake. Treatment with 4b–CS–NPs (but not the unloaded drug) reduced blood glucose levels (BGLs) and elevated cyclin D1 (CD1) gene expression indicating the successful ability of the NP system in promoting β-cells proliferation. Although treatment with free BI-605906 showed a modest reduction in BGLs, BI-605906-PLGA-MPs showed no improvement in BGLs. The latter could possibly be attributed to sub-optimal dosing. These results indicate that 4b–CS–NPs have the potential to lower BGLs by promoting β-cell proliferation and restoring pancreatic function. Further optimization is needed for BI-605906-PLGA-MPs, which may enhance therapeutic outcome by dual therapy.

Tailored Meal-Type Food Provision for Diabetes Patients Can Improve Routine Blood Glucose Management in Patients with Type 2 Diabetes: A Crossover Study.

This study aimed to determine whether patients with type 2 diabetes can benefit from a meal plan designed based on diabetes management guidelines to improve blood glucose levels. Participants were divided into intervention and control groups. The intervention group consumed a diabetic diet for 2 weeks, while the control group consumed their normal diet. After 2 weeks, the groups switched their dietary regimens. The participants' demographic and clinical characteristics were evaluated, including factors such as blood pressure, blood lipid levels, weight and waist circumference, blood glucose levels (self-monitored and continuously monitored), nutritional status, and blood-based markers of nutrient intake. The dietary intervention group improved waist circumference, body fat percentage, low-density lipoprotein cholesterol, triglyceride levels, and glucose. The energy composition ratio of carbohydrates and proteins changed favorably, and sugar intake decreased. In addition, the proportion of continuous glucose monitoring readings within the range of 180-250 mg/dL was relatively lower in the intervention group than that of the control group. Meals designed based on diabetes management guidelines can improve clinical factors, including stable blood glucose levels in daily life, significantly decrease the carbohydrate energy ratio, and increase the protein energy ratio. This study can help determine the role of dietary interventions in diabetes management and outcomes.

Glycemic homeostasis of ultrasound-assisted Murraya koenigii (Linn.) Spreng. bark extract in streptozocin-induced diabetes in rats

AbstractNumerous diseases have been linked to oxidative stress, emphasizing its role in pathogenicity. This study employed an ultrasound-assisted extraction process to obtain extracts from the bark of Murraya koenigii (L) Spreng. A thorough analysis was conducted on these dry extracts to determine their total phenolic and flavonoid content across four solvent fractions: n-hexane, ethyl acetate, n-butanol, and aqueous. Among the solvent fractions, ethyl acetate and n-butanol showed higher levels of total flavonoid content (TFC) and total phenolic content (TPC) compared to the others. The ethyl acetate fraction displayed the highest TPC (58.27 ± 4.20 mg GAE/g) and TFC (878.67 ± 40.38 mg QE/g) at 250 µg/mL concentration. Furthermore, the in-vitro antioxidant capacity of the ethyl acetate fraction was assessed for its ability to scavenge DPPH and hydrogen peroxide, revealing a concentration-dependent effect with IC50 values of 154.6 ± 6.2 and 55.12 ± 4.28 μg/mL, respectively. In a controlled experiment using streptozocin-induced diabetic rats, administering UMBE-EA at doses of 100 and 200 mg/kg notably improved blood glucose levels and body weight. Furthermore, several biochemical indicators, such as total protein levels, serum insulin, and the activities of enzymes like SGOT, SGPT, and ALP, as well as liver glycogen, showed significant enhancements. The antioxidant enzyme activities, including SOD, CAT, and GSH, returned to more favorable levels, and TABAR levels were normalized. In conclusion, the findings from this study strongly suggest that UMBE-EA possesses substantial anti-diabetic efficacy in Wistar rats, primarily attributed to its remarkable antioxidant properties and capacity to scavenge free radicals. These results provide valuable insights into the potential therapeutic benefits of UMBE-EA in diabetes management.